investmentNovo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discoveryThe Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation … more ➔
licensingJazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCelleraDublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and … more ➔
clinical dataF2G’s oral antifungal clears Phase III hurdleUK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening … more ➔
RegulatoryFDA opens path for uniQure’s Huntington’s gene therapy filingAfter months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130. more ➔
NIHPsychiatryFunding: HMNC and the Long Road to Precision PsychiatryWith a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important … more ➔
FundraisingAplagon raises €4.8m to expand antithrombotic into new Phase II trialFinnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing … more ➔
Venture capitalKos Biotechnology raises US$123m for Greek life sciences fundKos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem. more ➔
gene therapySensorion drops a gene therapy asset because of RegeneronSensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech … more ➔
LicensingNovartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bnOrionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug … more ➔
FinancingHeidelberg-based Veraxa ventures onto Nasdaq in turbulent market environmentVeraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading … more ➔
NIH
